Exploring the shared mechanism of fatigue between systemic lupus erythematosus and myalgic encephalomyelitis/chronic fatigue syndrome: monocytic dysregulation and drug repurposing
Authors:
Open Access
- 7 January 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1440922
Abstract
Background: SLE and ME/CFS both present significant fatigue and share immune dysregulation. The mechanisms underlying fatigue in these disorders remain unclear, and there are no standardized treatments. This study aims to explore shared mechanisms and predict potential therapeutic drugs for fatigue in SLE and ME/CFS.Methods: Genes associated with SLE and ME/CFS were collected from disease target and clinical sample databases to identify overlapping genes. Bioinformatics analyses, including GO, KEGG, PPI network construction, and key target identification, were performed. ROC curve and correlation analysis of key targets, along with single-cell clustering, were conducted to validate their expression in different cell types. Additionally, an inflammation model was established using THP-1 cells to simulate monocyte activation in both diseases in vitro, and RT-qPCR was used to validate the expression of the key targets. A TF-mRNA-miRNA co-regulatory network was constructed, followed by drug prediction and molecular docking.Results: Fifty-eight overlapping genes were identified, mainly involved in innate immunity and inflammation. Five key targets were identified (IL1β, CCL2, TLR2, STAT1, IFIH1). Single-cell sequencing revealed that monocytes are enriched with these targets. RT-qPCR confirmed significant upregulation of these targets in the model group. A co-regulatory network was constructed, and ten potential drugs, including suloctidil, N-Acetyl-L-cysteine, simvastatin, ACMC-20mvek, and camptothecin, were predicted. Simvastatin and camptothecin showed high affinity for the key targets.Conclusion: SLE and ME/CFS share immune and inflammatory pathways. The identified key targets are predominantly enriched in monocytes at the single-cell level, suggesting that classical monocytes may be crucial in linking inflammation and fatigue. RT-qPCR confirmed upregulation in activated monocytes. The TF-mRNA-miRNA network provides a foundation for future research, and drug prediction suggests N-Acetyl-L-cysteine and camptothecin as potential therapies.Keywords
Funding Information
- National Natural Science Foundation of China
- Zhejiang Chinese Medical University
This publication has 97 references indexed in Scilit:
- Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli‐1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal CellsArthritis & Rheumatology, 2021
- Immunological pathogenesis and treatment of systemic lupus erythematosusWorld Journal of Pediatrics, 2019
- Expression and Function of hsa-miR-6165 in Human Cell Lines and During the NT2 Cell Neural Differentiation ProcessJournal of Molecular Neuroscience, 2017
- Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus ErythematosusClinical Reviews in Allergy & Immunology, 2017
- Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort studyAtherosclerosis, 2015
- Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an updateQuality of Life Research, 2014
- N‐acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2012
- Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as Susceptibility Loci for Systemic Lupus Erythematosus in a Large-Scale Multiracial Replication StudyThe American Journal of Human Genetics, 2012
- Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndromeCytokine, 1991
- Suloctidil-induced hepatotoxicityGastroenterology, 1988